ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00524264
Recruitment Status : Completed
First Posted : September 3, 2007
Results First Posted : October 1, 2009
Last Update Posted : October 1, 2009
Sponsor:
Information provided by:
Allergan

Brief Summary:
This is a 16-day study to evaluate the safety and efficacy of ketorolac eye drops for the treatment of inflammation and pain associated with cataract surgery.

Condition or disease Intervention/treatment Phase
Cataract Extraction Pain Inflammation Drug: ketorolac Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 248 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Study Start Date : October 2007
Actual Primary Completion Date : April 2008
Actual Study Completion Date : April 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cataract
Drug Information available for: Ketorolac

Arm Intervention/treatment
Experimental: 1 Drug: ketorolac

Ophthalmic drops, BID pre- and post-operation, and 6 doses on surgery day.

Placebo


Placebo Comparator: 2 Drug: ketorolac

Ophthalmic drops, BID pre- and post-operation, and 6 doses on surgery day.

Placebo





Primary Outcome Measures :
  1. Resolution of Post Operative Inflammation [ Time Frame: Day 14 ]

Secondary Outcome Measures :
  1. Ocular Pain [ Time Frame: Day 1 ]
  2. Mean Pupil Area [ Time Frame: Day 0 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients undergoing cataract surgery

Exclusion Criteria:

  • Uncontrolled ocular disease in cataract surgery eye

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00524264


Locations
United States, California
Artesia, California, United States
Sponsors and Collaborators
Allergan
Investigators
Study Director: Medical Director Allergan

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Therapeutic Area Head, Allergan, Inc.
ClinicalTrials.gov Identifier: NCT00524264     History of Changes
Other Study ID Numbers: 191578-005
First Posted: September 3, 2007    Key Record Dates
Results First Posted: October 1, 2009
Last Update Posted: October 1, 2009
Last Verified: August 2009

Additional relevant MeSH terms:
Inflammation
Cataract
Pathologic Processes
Lens Diseases
Eye Diseases
Ketorolac
Ketorolac Tromethamine
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action